Insulin glargine (GLAR) improves health related quality of life (HRQOL) in patients with type 2 diabetes (T2DM) inadequately controlled on sulfonylurea plus metformin (SU plus MET)

被引：0

|

作者：

Vinik, AI

Dailey, G

Zhang, Q

机构：

来源：

DIABETES | 2005年 / 54卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A142 / A142

页数：1

相关论文

共 50 条

[1] Insulin glargine improves health related quality of life in patients with type 2 diabetes inadequately controlled on sulfonylurea plus metformin
Vinik, AI
Dailey, G
Zhang, Q
[J]. DIABETOLOGIA, 2005, 48 : A312 - A312
[2] Triple therapy in type 2 diabetes (T2DM): Benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU plus MET) in insulin-naive patients
Rosenstock, J
Sugimoto, D
Strange, P
Stewart, J
Soltes-Rak, E
Dailey, G
[J]. DIABETES, 2004, 53 : A145 - A145
[3] Change in lipid variables with insulin glargine versus pioglitazone in T2DM patients inadequately controlled on a sulfonylurea or metformin
McGill, J. B.
Traylor, L.
Dwarakanathan, A.
[J]. DIABETOLOGIA, 2007, 50 : S506 - S506
[4] Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Seewaldt-Becker, Elke
Weimer, Marc
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2013, 62 : A279 - A279
[5] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Vedel, Anita
Roux, Christiansen Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A280 - A280
[6] Efficacy and Safety of Dapagliflozin in Patients with T2DM Inadequately Controlled on Metformin Plus Sulfonylureas According to Background Sulfonylurea
Matthaei, Stephan
Bowering, Keith
Rohwedder, Katja
Grohl, Anke
Johnsson, Eva
[J]. DIABETES, 2015, 64 : A332 - A332
[7] Efficacy of dapagliflozin plus saxagliptin vs insulin glargine at 52 weeks in patients with type 2 diabetes inadequately controlled by metformin with or without sulfonylurea
Vilsboll, T.
Ekholm, E.
Johnsson, E.
Garcia-Sanchez, R.
Dronamraju, N.
Jabbour, S. A.
Lind, M.
[J]. DIABETOLOGIA, 2018, 61 : S380 - S380
[8] Health-related quality of life (HRQL) in patients with type 2 diabetes (T2DM), receiving add-on therapy with insulin glargine (GLAR) or pioglitazone (PIO)
Oster, G.
Meneghini, L. F.
Schwartz, S.
Zhang, Q.
[J]. DIABETES, 2006, 55 : A477 - A477
[9] BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (MET plus SU)
Pacou, M.
Taieb, V
Abrams, K. R.
Diels, J.
van Sanden, S.
Garg, M.
Schroeder, M.
Kaur, V
Nielsen, A. T. N.
Nuhoho, S.
Neslusan, C.
Hemels, M.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A431 - A431
[10] Clinical Characteristics, Quality Measure Attainment, and Diabetes-Related Healthcare Costs in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Metformin (MET) and Sulfonylurea (SU)
Lafeuille, Marie-Helene
Gravel, Jonathan
Bailey, Robert A.
Martin, Silas
Garber, Lawrence
Duh, Mei Sheng
Lefebvre, Patrick
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 447 - 448

← 1 2 3 4 5 →